McKesson (MCK) revenue breakdown
By segment, North American Pharmaceutical is the largest at 84% of fiscal 2026 revenue; Oncology & Multispecialty grew fastest, 26% a year over 2 years.
By region, United States is the largest at 83% of fiscal 2020 revenue, growing 5% a year over 3 years.
Revenue by segment
Fiscal years, as McKesson reports them in its 10-K filings; fiscal 2026 total $402.4B.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North American Pharmaceutical | — | — | — | — | — | — | — | $261.4B | $304.5B | $336.7B | 84% |
| Oncology & Multispecialty | — | — | — | — | — | — | — | $30.5B | $36.9B | $48.4B | 12% |
| Medical-Surgical Solutions | $6.2B | $6.6B | $7.6B | $8.3B | $10.1B | $11.6B | $11.1B | $11.3B | $11.4B | $11.5B | 3% |
| Prescription Technology Solutions | — | — | $2.5B | $2.7B | $2.9B | $3.9B | $4.4B | $4.8B | $5.2B | $5.8B | 1% |
| U.S. Pharmaceutical | $155.2B | $162.6B | $166.2B | $181.7B | $189.3B | $212.1B | $240.6B | — | — | — | — |
| European Pharmaceutical Solutions | $24.8B | $27.3B | — | — | — | — | — | — | — | — | — |
| International | — | — | $38.0B | $38.3B | $36.0B | $36.3B | $20.6B | — | — | — | — |
| Other | $12.2B | $11.8B | — | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as McKesson reports them in its 10-K filings; fiscal 2020 total $231.1B.
| Regions | 2017 | 2018 | 2019 | 2020 | Share |
|---|---|---|---|---|---|
| United States | $164.4B | $169.9B | $176.3B | $192.7B | 83% |
| Foreign | $34.1B | $38.4B | $38.0B | $38.3B | 17% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MCK.
Open MCK in InvestinglyQuestions
Where does McKesson make its money?
In fiscal 2026, by segment: North American Pharmaceutical $336.7B, Oncology & Multispecialty $48.4B, Medical-Surgical Solutions $11.5B, Prescription Technology Solutions $5.8B.
From McKesson's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.